Form 4: Theravance Biopharma Director Receives Equity Awards

Director Susannah Gray has been granted 6,009 ordinary shares and 13,398 stock options as part of her compensation package.

Summary

• Susannah Gray, a Director at Theravance Biopharma, Inc., acquired 6,009 ordinary shares on June 12, 2026.
• The acquisition was an equity grant with a transaction price of $0.00 per share.
• Gray also received 13,398 share options with an exercise price of $16.64 per share.
• Following these transactions, Gray's total direct beneficial ownership increased to 48,146 ordinary shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive administrative event, reflecting standard corporate governance and continued insider commitment.

Positives

• Increased insider alignment with shareholders through equity-based compensation.
• The exercise price for the new options is set at $16.64, indicating a target for future share price appreciation.
• Director maintains a significant stake in the company with over 48,000 shares held directly.

Negatives

• The filing does not disclose any immediate cash investment by the director, as these were grants rather than open-market purchases.

Risks

• The options are subject to vesting requirements, meaning the full benefit is contingent upon the director's continuous service.

Future Outlook

The granted options vest in 1/12th increments monthly or fully at the next annual meeting, suggesting a minimum one-year service expectation for the director to realize the full grant value.

Management Comments

• This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date.

Industry Context

StockSavvy.ai notes that equity-based compensation for directors is a standard practice in the biotechnology sector to ensure board members are incentivized to drive long-term shareholder value rather than short-term gains.

Comparison to Industry Standards

• The grant size is consistent with director compensation packages at peer mid-cap biopharmaceutical companies.
• The 10-year expiration window for options is a standard duration for executive and director equity incentives in the U.S. market.

Corporate Governance

Related Party Transactions

• The issuance of equity to a director is a standard related party transaction disclosed under Section 16(a) of the Securities Exchange Act.

Stakeholder Impact

• Shareholders may view the director's increased equity stake as a sign of confidence in the company's long-term prospects.

Next Steps

• Monthly vesting of the 13,398 share options over the next year.
• Potential full vesting of remaining options at the next annual shareholders' meeting.

Key Dates

Recommendation

This filing represents a routine administrative update regarding director compensation and does not contain new material information regarding the company's clinical trials, revenue, or strategic direction that would alter a standard investment thesis.

Keywords

Theravance Biopharma, TBPH, Insider Trading, Form 4, Director Compensation, Stock Options, Equity Grant, Susannah Gray